帕金森氏症藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按作用機制、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球帕金森氏症藥物市場價值為 55.5 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 7.45%。帕金森氏症是一種慢性進行性中樞神經系統神經退化性疾病，主要影響運動控制。其特徵是一系列運動症狀，也可能涉及非運動症狀。靜止性震顫是帕金森氏症的典型症狀。這些不自主的顫抖動作通常發生在受影響的肢體處於休息狀態時，並且經常伴隨手指有節奏的「滾動藥丸」運動。肌肉僵硬和被動運動阻力增加是帕金森氏症的常見症狀。這種僵硬會影響各個肌肉群並導致身體不適。隨著帕金森氏症的進展，可能會出現平衡問題和跌倒傾向。患者可能難以保持直立姿勢，並可能出現不明原因的跌倒。帕金森氏症可能涉及一系列非運動症狀，包括情緒變化（如憂鬱和焦慮）、睡眠障礙、認知障礙、自主神經功能障礙（如便秘和直立性低血壓）和感覺變化。

主要市場促進因素

技術進步

主要市場挑戰

副作用和耐受性

主要市場趨勢

以患者為中心的方法

目錄

第 1 章：產品概述

第2章：研究方法

第 3 章：執行摘要

第4章：顧客之聲

第 5 章：全球帕金森氏症藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依作用機轉分類（多巴胺激動劑、抗膽鹼能藥物、MAO-B 抑制劑、金剛烷胺、卡比多巴-左旋多巴、COMT 抑制劑和其他作用機制）
  • 按配銷通路（零售藥局、醫院藥局、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：亞太地區帕金森氏症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第7章：歐洲帕金森氏症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美帕金森氏症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第9章：南美洲帕金森氏症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲帕金森氏症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球帕金森氏症藥物市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• GSK plc
• Teva Pharmaceuticals Industries Ltd
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Kissei Pharmaceutical Co., Ltd.
• AstraZeneca Plc
• Prevail Therapeutics (Eli Lilly and Company)
• Newron Pharmaceuticals SPA

第 17 章：策略建議

第18章調查會社について,免責事項

Global Parkinson's Disease Drugs Market was valued at USD 5.55 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.45% through 2030. Parkinson's disease is a chronic and progressive neurodegenerative disorder of the central nervous system that primarily affects movement control. It is characterized by a range of motor symptoms and can also involve non-motor symptoms. Resting tremors are a hallmark symptom of Parkinson's disease. These involuntary shaking movements typically occur when the affected limb is at rest and often involve a rhythmic "pill-rolling" motion of the fingers. Muscle stiffness and increased resistance to passive movement are common in Parkinson's disease. This rigidity can affect various muscle groups and lead to a sense of physical discomfort. Balance problems and a tendency to fall can develop as Parkinson's disease progresses. Individuals may have difficulty maintaining an upright posture and may experience unexplained falls. Parkinson's disease can involve a range of non-motor symptoms, including mood changes (such as depression and anxiety), sleep disturbances, cognitive impairment, autonomic dysfunction (such as constipation and orthostatic hypotension), and sensory changes.

Key Market Drivers

Advancements in Technology

Implantable or wearable devices that deliver medication continuously or on-demand have been developed. These devices can provide a more stable and consistent drug delivery, reducing motor fluctuations and the need for frequent dosing. Advances in drug formulation techniques have led to the development of extended-release and controlled-release formulations. These formulations can help maintain therapeutic drug levels in the body over an extended period, reducing the frequency of medication administration. Inhalable levodopa formulations have been developed to provide rapid relief of motor symptoms. These inhalers can be particularly beneficial for patients who experience sudden "off" periods. Research is ongoing to identify and develop neuroprotective drugs that may slow the progression of Parkinson's disease. These drugs aim to protect and preserve dopamine-producing neurons in the brain. Advances in genetic testing and biomarker identification are enabling more personalized treatment approaches. Tailoring medication regimens to an individual's genetic profile and disease stage can optimize treatment outcomes. Prodrugs are inactive compounds that convert into active drugs within the body. Some prodrugs have been designed to improve the delivery of levodopa, the primary treatment for PD, and reduce side effects.

Key Market Challenges

Side Effects and Tolerability

Some Parkinson's disease drugs, particularly levodopa, can lead to motor fluctuations, including "on-off" periods, dyskinesias (involuntary movements), and wearing-off phenomena. These fluctuations can be disruptive and challenging to manage. Many Parkinson's drugs can cause gastrointestinal side effects such as nausea, vomiting, and constipation. These side effects can affect medication absorption and patient compliance. Dopaminergic medications, including dopamine agonists, can lead to psychiatric side effects like hallucinations, impulse control disorders, and mood disturbances. These can have a significant impact on a patient's mental well-being. Some medications may exacerbate cognitive impairment in Parkinson's disease patients, particularly in advanced stages of the disease. This can include impairments in memory, attention, and executive function. Parkinson's disease drugs can lower blood pressure, leading to orthostatic hypotension, a condition where blood pressure drops significantly upon standing. This can result in dizziness, falls, and fainting. Medications can affect sleep patterns, leading to insomnia or excessive daytime sleepiness. Sleep disturbances can further worsen the quality of life for patients. Dopamine agonists can sometimes cause impulsive behaviors, including gambling and hypersexuality. These behaviors can strain relationships and have financial and social consequences. Patients with Parkinson's disease often take multiple medications to manage their symptoms and comorbid conditions. Drug interactions can occur, potentially leading to adverse effects or reduced drug efficacy.

Key Market Trends

Patient-Centric Approaches

Recognizing that Parkinson's disease can manifest differently in each patient, healthcare providers are increasingly tailoring treatment plans to the specific needs and characteristics of individuals. Genetic testing and other biomarker assessments may be used to determine the most appropriate medications and dosages. Patient-centric care emphasizes the importance of involving patients in their own care decisions. It considers their preferences, values, and goals when developing treatment plans. This approach fosters a collaborative relationship between patients and healthcare providers. Shared decision-making is a fundamental aspect of patient-centric care. It involves a two-way exchange of information and decision-making between patients and healthcare providers to determine the most suitable treatment options based on the patient's preferences and circumstances. Educating patients about their condition, treatment options, and self-management strategies is crucial. Empowering patients with knowledge enable them to actively participate in their care and make informed decisions. A patient-centric approach often involves a multidisciplinary care team, including neurologists, physical therapists, occupational therapists, speech therapists, and mental health professionals. This team collaborates to address the diverse needs of Parkinson's patients.

Key Market Players

• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• GSK plc
• Teva Pharmaceuticals Industries Ltd
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Kissei Pharmaceutical Co., Ltd.
• AstraZeneca Plc
• Prevail Therapeutics (Eli Lilly and Company)
• Newron Pharmaceuticals SPA

Report Scope:

In this report, the Global Parkinson's Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Parkinson's Disease Drugs Market, By Mechanism of Action:

• Dopamine Agonists
• Anticholinergic
• MAO-B Inhibitors
• Amantadine
• Carbidopa-levodopa
• COMT Inhibitors
• Other Mechanisms of Action

Parkinson's Disease Drugs Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Others

Global Parkinson's Disease Drugs Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Parkinson's Disease Drugs Market.

Available Customizations:

Global Parkinson's Disease Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Parkinson's Disease Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action)
  • 5.2.2. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Parkinson's Disease Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Mechanism of Action
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Parkinson's Disease Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Mechanism of Action
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. India Parkinson's Disease Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Mechanism of Action
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Australia Parkinson's Disease Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Mechanism of Action
      • 6.3.3.2.2. By Distribution Channel
  • 6.3.4. Japan Parkinson's Disease Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Mechanism of Action
      • 6.3.4.2.2. By Distribution Channel
  • 6.3.5. South Korea Parkinson's Disease Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Mechanism of Action
      • 6.3.5.2.2. By Distribution Channel

7. Europe Parkinson's Disease Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Mechanism of Action
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Parkinson's Disease Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Mechanism of Action
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Parkinson's Disease Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Mechanism of Action
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Spain Parkinson's Disease Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Mechanism of Action
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Parkinson's Disease Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Mechanism of Action
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. United Kingdom Parkinson's Disease Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Mechanism of Action
      • 7.3.5.2.2. By Distribution Channel

8. North America Parkinson's Disease Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Mechanism of Action
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Parkinson's Disease Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Mechanism of Action
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Mexico Parkinson's Disease Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Mechanism of Action
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Canada Parkinson's Disease Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Mechanism of Action
      • 8.3.3.2.2. By Distribution Channel

9. South America Parkinson's Disease Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Mechanism of Action
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Parkinson's Disease Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Mechanism of Action
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Parkinson's Disease Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Mechanism of Action
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Parkinson's Disease Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Mechanism of Action
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Parkinson's Disease Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Mechanism of Action
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Parkinson's Disease Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Mechanism of Action
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Parkinson's Disease Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Mechanism of Action
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Parkinson's Disease Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Mechanism of Action
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Parkinson's Disease Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Amneal Pharmaceuticals LLC
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. AbbVie Inc.
• 16.3. Boehringer Ingelheim International GmbH
• 16.4. GSK plc
• 16.5. Teva Pharmaceuticals Industries Ltd
• 16.6. Pfizer Inc.
• 16.7. Novartis AG
• 16.8. F. Hoffmann-La Roche Ltd
• 16.9. Kissei Pharmaceutical Co., Ltd.
• 16.10. AstraZeneca Plc
• 16.11. Prevail Therapeutics (Eli Lilly and Company)
• 16.12. Newron Pharmaceuticals SPA

17. Strategic Recommendations

18. About Us & Disclaimer